KR20130103945A - Flavone compounds with 15-hydroxyprostaglandin dehydrogenase inhibitory activity and uses thereof - Google Patents

Abstract

PURPOSE: A flavone compound is provided to increase PGE2 in cells with less cytotoxicity and to enable effective wound healing, thereby being used as an active ingredient of a composition and a cosmetic composition for preventing and treating diseases which need the increase of PGE2. CONSTITUTION: A pharmaceutical composition for preventing and treating diseases which need the increase of PEG2, such as inflammatory diseases, tumor, Alzheimer's disease, and atherosclerosis contains a compound of chemical formula 1 as an active ingredient. The compound of chemical formula 1 suppresses 15-hydroxyprostaglandin dehydrogenase (15-hydroxy PGDH) and increases PGE2. A cosmetic composition for improving scalp and skin regeneration contains the compound of chemical formula 1 as an active ingredient.

Description

Inhibitory effect of flavone compound on 15-hydroxyprostaglandin dehydrogenase activity and its use {FLAVONE COMPOUNDS WITH 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE INHIBITORY ACTIVITY AND USES THEREOF}

The present invention relates to a composition for the prevention and treatment of diseases requiring an increase in PGE ₂ containing a flavone compound and for the treatment of wounds, blood flow improvement, bone formation, ulcer treatment, hair loss, scalp improvement, and cosmetic composition for skin regeneration. will be.

Prostaglandin (PG) E ₂ is the major eicosanoid produced by epithelial cells of the cornea, which regulates somatic division, migration, and morphology through the EP2 receptor (Joyce et al., 1989). Jumblatt, 1994; Jumblatt and Paterson, 1991). Arachidonic acid is formed in membrane phospholipids by phospholipase A2. PGE ₂ is formed by PG synthase from PGH ₂ derived from arachidonic acid by cyclooxygenase (COX) (Dey et al., 2006). PGE ₂ is key to the regulation of many physiological functions and is considered a major mediator of inflammation (Coleman et al., 1994; Griffiths, 1999). Two types of COX subtypes have been identified. COX-1 is constantly expressed in various tissues, including the stomach, while COX-2 is induced by cytokines, growth factors, carcinogenic promoters and other substances (Crofford, 1997). Prostaglandins (PGs) are not stored within cells but are released extracellularly to act on autocrine or on other neighboring cells (paracrine). The newly synthesized PGE ₂ is ejected extracellularly by diffusion method or by multidrug resistance 4 (MRP4), which is known to carry PGE ₂ effectively in ATP-dependent conditions (Reid et al., 2003; Schuster, 2002). Extracellular PGE ₂ is active through EP receptors, G protein-coupled receptors on the cell surface that activate several signaling processes (Zhu et al., 2006). Subsequently, pericellular PGE ₂ is reabsorbed through the PG transporter (PGT) (Schuster, 1998), followed by the cytoplasmic enzyme NAD ⁺ -dependent 15-hydroxyprostaglandin dehydrogenase (15). metabolized rapidly by -hydroxyprostaglandin dehydrogenase (15-PGDH) (Anggard and Samuelsson, 1964) (see FIG. 1).

15-hydroxyprostaglandin dehydrogenase (15-PGDH) is an important enzyme involved in the biological inactivation of PG, such as PGE ₂ , which is ubiquitous in mammalian tissues (Anggard, 1966). 15-PGDH enzymes of NAD ⁺ specific Type I and NADP ⁺ specific Type II were identified. However, type II was later identified as carbonyl reductase (Wermuth, 1981), and it is believed that type I is an important enzyme involved in the biological inactivation of PG.

In addition, PGE ₂ has been shown to cure gastric ulcers (Araki et al., 2002; Gudis and Sakamoto, 2005; Halter et al., 2001; Hatazawa et al., 2007; Miura et al., 2004; Mizuno et al., 1997; Shigeta et al., 1998; Ukawa et al., 1998; Wallace, 2008), skin wound healing (Choung et al., 1998; Futagami et al., 2002; Kohyama et al., 2001; Parekh et al., 2009; Watanabe et al., 1996; Wilgus et al., 2004) and in human hair follicle cells (Colombe et al., 2008; Michelet et al., 2008). Wound healing is a complex process involving many types of cells, water soluble mediators, and extracellular matrix. In the adult dermis, the healing process begins with hemostasis and inflammation, producing tissue in its original state, but often leaving scars (Singer and Clark, 1999). PGE ₂ has four EP receptors through keratinocytes (Konger et al., 1998), dendritic cells (Harizi et al., 2003), and fibroblasts (Kolodsick et al., To regulate the activity of various cells, including 2003). Thus, sophisticated expression of receptors is important in determining the overall effect of PGE ₂ with proinflammatory or anti-inflammatory effects. EP is also regulated differently during wound healing in fetuses or adults (Li et al., 2000).

The wound healing process consists of three stages. The stages are the stages of inflammation, proliferation and maturation, which are characterized by hemostasis and inflammation. The second stage of wound healing is the proliferation phase, which involves epithelialization, angiogenesis, granulation tissue formation and collagen deposition, and is the main stage in the assimilation of wound healing. Epithelialization occurs early in wound regeneration, fibroblasts are differentiated, skin substances are produced, and collagen is produced. The skin matrix is deposited on the wound site and collagen deposits as the wound site goes through the final stage of regeneration. This stage of wound healing involves the complex interaction of cells with cytokines that work with them, and many other cytokines that are currently being studied in vitro include TGF-β, EGF and IGF-1. In recent years, mediator integrals that are involved in more wound healing have been identified.

Re-epithelialization is an important action in wound healing. Wound healing is a complex process involving clot formation, inflammatory response, granulation of granulation tissue, deposition and remodeling of extracellular matrix (ECM) (Clark, 1996). Wound healing requires mediators released from inflammatory cells, fibroblasts, and keratinocytes as well as cell interactions in the epidermis and dermis (Martin, 1997). Re-epithelialization of keratinocytes is a process by which cells migrate to the epidermis of the wound and mitosis (Santoro and Gaudino, 2005). Many factors that affect wound healing include growth factors, cytokines, metalloproteinases, and extracellular matrix (ECM) proteins (Coulombe, 2003; Martin, 1997; Santoro and Gaudino, 2005). Some exogenous action of these factors has been shown to benefit the healing process (Werner and Grose, 2003). Was reported and reported by the bar for PGE ₂ by many studies as an important mediator of skin wound healing, PGE ₂ can suppress the differentiation of fibroblasts in muscle cells through EP2 receptor path ((Kolodsick et al., 2003 ) .

Therefore, the present inventors have studied to develop a material for wound healing. As a result, 7, 3 ', 4'-trimethoxyflavone increases PGE ₂ through the inhibition of 15-PGDH, so that skin wounds and wounds related to PGE ₂ are affected. It has been found to be useful in pharmaceutical compositions for wound healing such as cuts, abrasions and gastric ulcers, cosmetic compositions for skin regeneration and wound healing, and skin cosmetic compositions for increased hair density, hair growth and eyelash growth. The invention has been completed.

An object of the present invention, the composition for the prevention and treatment of diseases requiring an increase in PGE ₂ selected from the group consisting of inflammatory response disease, tumor disease, Alzheimer's disease and atherosclerosis containing the compound of formula (1) as an active ingredient To provide:

[Formula 1]

In Formula 1, R ₁ , R ₂ , R ₃ , R ₄ , R ₅ , and R ₆ are each independently hydrogen (H), hydroxy group (OH), or methoxy group (OCH ₃ ).

In addition, it is an object of the present invention to provide a cosmetic composition for hair loss, scalp improvement and skin regeneration comprising the compound of formula 1 as an active ingredient:

[Formula 1]

.

.

In Formula 1, R ₁ , R ₂ , R ₃ , R ₄ , R ₅ , and R ₆ are each independently hydrogen (H), hydroxy group (OH), or methoxy group (OCH ₃ ).

In order to achieve the above object, the present invention is to prevent the disease requiring an increase in PGE ₂ selected from the group consisting of inflammatory response disease, tumor disease, Alzheimer's disease and atherosclerosis containing the compound of formula (1) as an active ingredient And the therapeutic compositions:

[Formula 1]

In Formula 1, R ₁ , R ₂ , R ₃ , R ₄ , R ₅ , and R ₆ are each independently hydrogen (H), hydroxy group (OH), or methoxy group (OCH ₃ ).

In addition, in order to achieve the above object, the present invention provides a cosmetic composition for hair loss, scalp improvement and skin regeneration comprising the compound of formula 1 as an active ingredient:

[Formula 1]

.

.

In Formula 1, R ₁ , R ₂ , R ₃ , R ₄ , R ₅ , and R ₆ are each independently hydrogen (H), hydroxy group (OH), or methoxy group (OCH ₃ ).

Low isoflavone compounds of the present invention are cytotoxic, by inhibiting 15-PGDH to metabolize PGE ₂ increases the PGE _2, the mRNA expression level of MRP4, PGT, COX-1 and COX-2 related to the level of PGE ₂ By regulating PGE ₂ intracellularly, it is possible to effectively heal wounds. Therefore, the composition for the prevention and treatment of diseases requiring increased PGE ₂ and wound treatment, blood flow improvement, bone formation, ulcer treatment, hair loss, scalp improvement and skin It can be usefully used as an active ingredient of a cosmetic composition for regeneration.

: PGE₂;
PL: 포스포리피드(phospholipid);
PLA₂: 포스포리파아제 A₂(phospholipase A₂); 및
PGT: 프로스타글란딘 트랜스포터(prostaglandin transporter).
도 2는 인간 각질 세포인 HaCaT 세포에서 7, 3', 4'-트리메톡시플라본에 의한 COX-1/2, MRP4 및 PGT의 mRNA 발현량을 나타낸 그래프이다;
Statistically significant p<0.05.
도 3은 인간 각질 세포인 HaCaT 세포에서 7, 3', 4'-트리메톡시플라본에 의한 상처 치료 분석을 나타내는 역상현미경(×100) 사진이다;
control: 약물 미처리 음성 대조군;
TMF: 7, 3', 4'-트리메톡시플라본 처리 실험군; 및
TGF-β1: TGF-β1 처리 양성 대조군.1 is a schematic representation of the action of molecules related to PGE _{2 in} and out of cells;
AA: arachidonic acid;

: PGE ₂ ;
PL: phospholipid;
PLA ₂ : phospholipase A ₂ (phospholipase A ₂ ); And
PGT: prostaglandin transporter.
Figure 2 is a graph showing the mRNA expression levels of COX-1 / 2, MRP4 and PGT by 7, 3 ', 4'-trimethoxyflavone in HaCaT cells, which are human keratinocytes;
Statistically significant p <0.05.
FIG. 3 is a reverse micrograph (× 100) showing wound treatment analysis by 7, 3 ′, 4′-trimethoxyflavones in HaCaT cells, human keratinocytes;
control: untreated negative control;
TMF: 7, 3 ', 4'-trimethoxyflavone treatment experimental group; And
TGF-β1: TGF-β1 treated positive control.

Hereinafter, the present invention will be described in detail.

The present invention provides a composition for the prevention and treatment of diseases requiring an increase in PGE ₂ selected from the group consisting of an inflammatory response disease, a tumor disease, Alzheimer's disease and atherosclerosis containing the compound of formula 1 as an active ingredient. :

[Formula 1]

In Formula 1, R ₁ , R ₂ , R ₃ , R ₄ , R ₅ , and R ₆ are each independently hydrogen (H), hydroxy group (OH), or methoxy group (OCH ₃ ).

Preferably, the disease is selected from the group consisting of hair loss, scalp disease, peptic ulcer, stomatitis, oral ulcer, fracture, peripheral vascular disease, skin wound and burn, but is not limited thereto.

The skin wound is preferably selected from the group consisting of cuts, wounds, cuts, abrasions and gastric ulcers, but is not limited thereto.

In the compound of Formula 1, R ₁ is a methoxy group or hydrogen;

R ₂ is a methoxy group;

R ₃ is a methoxy group, hydrogen or a hydroxy group;

R ₄ is a methoxy group or hydrogen;

R ₅ is a methoxy group or hydrogen; And

R ₆ is preferably a methoxy group, hydrogen or a hydroxy group, and R ₁ is a methoxy group in the compound of Formula 1;

R ₂ is a methoxy group; And

More preferably, R ₅ is a methoxy group, but is not limited thereto.

[Formula 2]

The methoxy group represented by Chemical Formula 1 is most preferably present at the positions of 7, 3 'and 4' in the backbone of the flavone by structure-activity relation (SAR). 15-PGDH Has an inhibitory effect.

The compound of Formula 1 preferably has PGE ₂ increasing activity, but is not limited thereto.

The compound of Formula 1 preferably has an activity of inhibiting 15-PGDH, but is not limited thereto.

In a specific embodiment of the present invention, the inventors of the present invention, 7, 3 ', 4'-trime in order to find a substance with high cytotoxic 15-PGDH inhibitory activity that metabolizes and reduces PGE ₂ of the seven flavones, Toxyflavones were selected and their 15-PGDH inhibitory activity and cytotoxicity were confirmed. As a result, 7 kinds of 7, 3 ', 4'-trimethoxyflavones (TMF), 3', 4'-dimethoxyflavones, 5, 7, 4'-trimethoxyflavones, 3 , 6, 3 ', 4'-tetramethoxyflavone, 3, 7-dihydroxy-3', 4'-dimethoxyflavone, 3, 5, 7, 3 ', 4'-pentamethoxyflavone and 5, 7, 3 'and 4'-tetramethoxyflavones all inhibited the activity of 15-PGDH, in particular 7, 3' and 4 '. It was confirmed that -trimethoxyflavone had the best 15-PGDH inhibitory activity and very low cytotoxicity (see Table 1).

Further, in another specific embodiment of the present invention, the inventors of the present invention have carried out enzyme immunization to determine the extracellular level of PGE ₂ as a substrate through the inhibition of 15-PGDH by 7, 3 ', 4'-trimethoxyflavone. As a result of the analysis, it was confirmed that PGE ₂ was increased by about 10 times by concentration of 7, 3 'and 4'-trimethoxyflavone (see Table 2).

Further, in another specific embodiment of the present invention, the inventors have found that the mRNAs of COX-1 / 2, MRP4 and PGT are 7, 3 ', 4'-trimethoxyflavones, molecules that determine PGE ₂ levels in and out of cells. As a result of performing real-time PCR to investigate the effect on the expression level, the mRNA expression level of COX-2 producing PGE ₂ was decreased, and the mRNA expression level of MRP4 involved in the extracellular transport of PGE ₂ was increased. , PGE ₂ via 15-PGDH inhibition by 7, 3 ', 4'-trimethoxyflavone Metabolic Inhibitory Effects of PGE ₂ Cells It can be seen that it is important to increase the level (see Fig. 2).

In addition, in another specific embodiment of the present invention, the inventors have reported that PGE ₂ is associated with wound healing such as skin wounds and gastric ulcers, and thus increases the level of PGE ₂ to 7, 3 ', 4'-tree. To determine if methoxyflavones are effective in healing wounds, a wound healing assay was performed to examine the process of wounding in human keratinocytes, HaCaT cells, and then healing by 7, 3 'and 4'-trimethoxyflavones. As a result, it was confirmed that the effect is similar to the positive control (see Fig. 3).

Thus, this was 7, 3 ', 4'-trimethoxy flavone of the present invention is less cytotoxic, the level of the cell and out of the PGE ₂ relating to effectively inhibit the enzyme 15-PGDH to metabolize PGE _2, and wound healing It regulates the mRNA expression of COX-1 / 2, MRP4 and PGT, which are molecules that regulate WC, and 7, 3 ', 4'-trimethoxyflavones have a wound healing effect, so that an increase in PGE ₂ is required. It can be seen that it can be usefully used as an active ingredient of the composition for preventing and treating diseases.

The composition for the prevention and treatment of related diseases requiring an increase in PGE ₂ containing the flavone of the present invention may further include a pharmaceutically acceptable additive, wherein the pharmaceutically acceptable additive may include starch, Gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, lactose, mannitol, malt, gum arabic, pregelatinized starch, corn starch, powdered cellulose, hydroxypropyl cellulose, opadry, starch glycolic acid Sodium, carnauba lead, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, white sugar, dextrose, sorbitol, talc and the like can be used. The pharmaceutically acceptable additive according to the present invention is preferably included 0.1 to 90 parts by weight based on the composition, but is not limited thereto.

That is, the composition of the present invention can be administered in various formulations of oral and parenteral administration at the time of actual clinical administration. In the case of formulation, a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, . &Lt; / RTI &gt; Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose ), Lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate talc may also be used. Oral liquid preparations include suspensions, solutions, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, and suppositories. Non-aqueous solvents and suspending agents may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

The composition of the present invention may be administered orally or parenterally according to a desired method, and externally or intraperitoneally, rectally, subcutaneously, intravenously, intramuscularly or intrathoracically It is preferable to select. The dosage varies depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and severity of disease.

The dosage of the composition of the present invention varies depending on the weight, age, sex, health condition, diet, time of administration, administration method, excretion rate and severity of the disease of the patient, the daily dosage is based on the amount of gallium extract 0.0001 to 100 mg / kg, preferably 0.001 to 10 mg / kg, and may be administered 1 to 6 times a day.

In addition, the present invention provides a cosmetic composition for hair loss, scalp improvement and skin regeneration comprising the compound of formula 1 as an active ingredient:

[Formula 1]

.

.

In Formula 1, R ₁ , R ₂ , R ₃ , R ₄ , R ₅ , and R ₆ are each independently hydrogen (H), hydroxy group (OH), or methoxy group (OCH ₃ ).

In the compound of Formula 1, R ₁ is a methoxy group or hydrogen;

R ₂ is a methoxy group;

R ₃ is a methoxy group, hydrogen or a hydroxy group;

R ₄ is a methoxy group or hydrogen;

R ₅ is a methoxy group or hydrogen; And

R ₆ is preferably a methoxy group, hydrogen or a hydroxy group, and R ₁ is a methoxy group in the compound of Formula 1;

R ₂ is a methoxy group; And

More preferably, R ₅ is a methoxy group, but is not limited thereto.

[Formula 2]

In a specific embodiment of the present invention, the present inventors selected 7, 3 ', 4'-trimethoxyflavones with high cytotoxicity and high 15-PGDH inhibitory activity which metabolize PGE ₂ among flavonoids, and 7, Inhibition of 15-PGDH by 3 'and 4'-trimethoxyflavones showed that the substrate PGE ₂ was increased by about 10-fold.

In addition, in another specific embodiment of the present invention, the inventors of the present invention, the mRNA of COX-1 / 2, MRP4 and PGT, 7, 3 ', 4'-trimethoxyflavone is a molecule that determines the level of PGE ₂ inside and outside the cell Confirmed that affect the expression level, PGE ₂ through 15-PGDH inhibition by 7, 3 ', 4'-trimethoxyflavone Metabolic Inhibitory Effects of PGE ₂ Cells It was found that it is important to increase the level, and this confirms that 7, 3 'and 4'-trimethoxyflavones, which increase the level of PGE ₂ , are effective in wound healing, and are important for hair growth and survival. It was confirmed that it can be usefully used as a composition for treating or preventing hair loss by showing an effect of inhibiting 15-PGDH which inactivates the mediator PGE ₂ very well.

Thus, this was 7, 3 ', 4'-trimethoxy flavone of the present invention is less cytotoxic, molecules which effectively inhibit the enzyme 15-PGDH to metabolize PGE _2, control of the level of intracellular PGE ₂ Regulates mRNA expression of COX-1 / 2, MRP4 and PGT, PGE ₂ , an important mediator of hair growth and survival Since it effectively increases the level, it can be usefully used as a composition for preventing hair loss, improving scalp, and skin regeneration.

The cosmetic composition containing the flavone of the present invention as an active ingredient may include a composition selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, and sphingolipids. Fats and oils, moisturizers, emollients, surfactants, organic and inorganic pigments organic powders, UV absorbers, preservatives, fungicides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, flavorings, blood circulation accelerators Other components, such as a restriction | limiting agent and purified water, can be mix | blended. In addition, the cosmetic composition of the present invention may be prepared in any formulation in which the cosmetic composition is usually prepared, and may be, for example, an emulsion, a cream, a lotion, a pack, a foundation, a lotion, a cosmetic liquid, a hair cosmetic, and the like.

In addition, the cosmetic composition containing a flavone for the skin of the present invention as an active ingredient skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisturizing lotion, nutrition lotion, massage cream, nutrition cream, moisture cream, hand Formulations of creams, foundations, essences, nutritional essences, packs, soaps, cleansing foams, cleansing lotions, cleansing creams, body lotions and body cleansers. When the formulation of the present invention is a paste, cream or gel, animal carriers, vegetable fibers, waxes, paraffins, starches, tracantes, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide, etc. may be used as carrier components. In the case of the solution or emulsion of the present invention, a solvent, a solvating agent or an emulsifying agent may be used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzo Fatty acid esters of ate, propylene glycol, 1,3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan. When the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used. When the formulation of the present invention is a surfactant-containing cleansing, the carrier component is an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, an isethionate, an imidazolinium derivative, a methyltaurate, a sarcosinate, a fatty acid amide. Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.

In addition, the composition containing the flavone of the present invention as an active ingredient may comprise a carrier or carrier mixture suitable for application to the hair. The carrier comprises a solvent and a vehicle component conventionally used in other carriers or hair care compositions, with about 0.5% to 99.5%, preferably about 5.0% to 99.5%, most preferably in the composition of the total hair composition Is present in about 10.0% to 90.0%. The solvent as the carrier is selected by the copolymer used, regardless of whether the formulated hair composition remains in the hair after use, such as hair spray, mousse, tonic, or the like, or is cleaned, such as shampoo, conditioner, and the like. Suitable solvents for use in the present invention include water, lower alcohols (ethanol, isopropanol, etc.), hydroalcoholic mixtures, hydrocarbons (isobutane, hexane, decene, etc.), acetone, halogenated hydrocarbons (freons, etc.), hydrocarbon esters (ethyl acetate, Dibutyl phthalate, etc.), volatile silicone derivatives, siloxanes (phenyl pentamethyl disiloxane, methoxypropyl heptamethyl cyclotetrasiloxane, chloropropyl pentamethyl disiloxane, hydroxypropyl pentamethyl disiloxane, octamethyl cyclotetrasiloxane, decamethyl Cyclopentasiloxane, etc.) and mixtures thereof.

Hereinafter, the present invention will be described in detail with reference to examples.

However, the following examples are only illustrative of the present invention in detail, and the content of the present invention is not limited by the examples.

< Example  1> 15- PGDH  Expression and purification

We purified 15-PGDH by preparing a 15-PGDH vector to purify 15-PGDH.

Specifically, PGEX-2T expression vector (Pharmacia Crop, USA) having a 15-PGDH cDNA sequence was transduced into the E. coli BL-21 lysS strain. Transduced strains were incubated in 500 ml of medium containing 50 ug / ml of empicillin until the OD ₆₀₀ value reached 0.6 at 37 ° C. and 220 rpm. Thereafter, 1 mM of isopropyl-1-thio-beta-D-galactoside (Isopropyl-1-thio-β-D-galactopyranoside, IPTG) was added thereto, followed by incubation at 25 ° C. for 12 hours. Cultured E. coli was obtained by centrifugation at 4 ° C. and 4000 g for 30 minutes, and the obtained cells were re-purified in 20 ml of cold cell lysis buffer (1 × PBS buffer at pH 7.4 including 1 mM EDTA and 0.1 mM DTT). It was suspended and sonicated four times at 10 DEG C for 10 seconds. Sonicated cells were centrifuged at 4 ° C. and 4000 g for 20 minutes and the supernatant was passed through a glutathione-Sepharose 4B column (Sigma, USA) adjusted with lysis buffer at 4 ° C. The column was washed with lysis buffer to an OD ₂₈₀ value of 0.005 or less, followed by 50 mM Tris-HCl pH 8.0, 1 mM EDTA (Sigma, USA) and 0.1 elution buffer (10 mM reduced glutathione (Sigma, USA)). mM DTT) was incubated at room temperature for 5 minutes to elute 15-PGDH on the column.

Purified 15-PGDH through the SDS-PAGE gel (Sigma, USA) electrophoresis was confirmed the concentration and purity.

< Example  2> 7, 3 ', 4'-trimethoxyflavone ( trimethoxyflavone , TMF 15- of) PGDH  Inhibitory activity and AML  Cytotoxicity Analysis in Cells

In order to find a substance with high inhibitory activity against 15-PGDH that metabolizes PGE ₂ and low cytotoxicity among flavonoids, the present inventors analyzed 15 kinds of 15-PGDH inhibitory activity using extracellular experiments and 7 kinds using AML-2 cells. The cytotoxic effects of flavonoids (Hillsborough, New Jersey, USA) were examined.

Specifically, the inventors of the present invention, 0.1 mM DTT (Sigma, USA), 0.25 mM NAD ⁺ (Sigma, USA), 15-PGDH (10 ug) purified in <Example 1>, 21 uM PGE ₂ (Sigma, USA ) And incubated with Tris-HCl buffer (50 mM, pH 7.5) mixed with different concentrations of flavonoids, and then treated with a fluorescence spectrophotometer, the NADH at 468 nm emission according to 340 nm excitation light. The 15-PGDH inhibitory activity was measured using a standard curve of NADH which measured the formation of (all experiments were repeated three times).

In addition, in vitro of drugs using AML cells ( in In vitro ) To determine the cytotoxicity, 8 × 10 ⁴ cells of AML-2 cells were dispensed in 90 ul α-MEM medium in 96-well plates, incubated for 12 hours, and treated with 7 flavonoids. After 72 hours of flavonoid treatment, 10 ul of MTT was added and incubated for 4 hours. After 4 hours, absorbance at 540 nm was measured using an ELISA microplate reader (Perkin-Elmer, Gly., USA).

As a result, 7, 3 ', 4'-trimethoxyflavone (TMF), 3', 4'-dimethoxyflavone, 5, 7, 4'-trimethoxyflavone, 3, 6 , 3 ', 4'-tetramethoxyflavone, 3, 7-dihydroxy-3', 4'-dimethoxyflavone, 3, 5, 7, 3 ', 4' -Pentamethoxyflavone and 5, 7, 3 ', 4'-tetramethoxyflavone inhibited the activity of 15-PGDH, in particular, 7, 3', 4'-trimethoxyflavone The 50% inhibitory concentration (IC ₅₀ ) on 15-PGDH activity was more effective at 0.41 uM than the other flavonoids, and the cytotoxicity at AML-2 was the lowest at 50% inhibitory concentration (IC ₅₀ )> 400 uM. (Table 1).

15-PGDH Inhibitory Activity and Cytotoxicity of Flavonoids Flavonoids 15-PGDH Suppression IC ₅₀ (uM) Cytotoxic IC ₅₀ (uM) 7, 3 ', 4'-trimethoxyflavone (7, 3', 4'-TMF) 0.41 > 400 3 ', 4'-dimethoxyflavone 1.76 386 5, 7, 4'-trimethoxyflavone 1.94 72.6 3, 6, 3 ', 4'-tetramethoxyflavone 3.10 > 400 3, 7-dihydroxy-3 ', 4'-dimethoxyflavone 3.67 7.4 3, 5, 7, 3 ', 4'-pentamethoxyflavone 4.10 61 5, 7, 3 ', 4'-tetramethoxyflavone 7.82 37.2

< Example  3> 7, 3 ', 4'-trimethoxyflavone ( trimethoxyflavone , 7, 3 ', 4'- TMF )of PGE ₂  Emission analysis

To the inventors to determine whether they affect the PGE ₂ in a cell by 7, 3 ', 4'-trimethoxy flavone of inhibiting 15-PGDH PGE ₂ Enzyme immunoassay was performed.

Specifically, lung cancer cell lines A549 cells (5 × 10 ⁵ cells) were dispensed in 6-well plates and cultured in DMEM medium at 37 ° C., 5% CO ₂ incubator. 7, 3 ', 4'-trimethoxyflavone (TMF) or 3', 4'-dimethoxyflavone having good 15-PGDH inhibitory activity among the flavonoids found in <Table 1> of <Example 2> in cultured cells (Dimethoxyflavone) was treated with concentrations of 10 times (10 × IC ₅₀ ) and 100 times (100 × IC ₅₀ ) of IC ₅₀ values for 15-PGDH inhibition, and then media were obtained after 6 hours. Control growth of PGE ₂ in the culture medium obtained in HaCaT cells compared to the (drug-treated group) is PGE ₂ Measurements were made using an enzyme immunoassay kit (Thermo Scientific, USA).

As a result, in the case of treatment with 7, 3 ', 4'-trimethoxyflavone and 3', 4'-dimethoxyflavone, the concentration-dependent extracellular PGE ₂ Levels increased more than 10-fold, in particular, it was found that the inhibitory effect by 7, 3 ', 4'- trimethoxy flavone is superior (Table 2).

Accordingly, the inventors have identified 7, 3 ', 4'-trimethoxyflavone as PGE ₂ It was selected as a potent 15-PGDH inhibitor that increases the level.

15-PGDH Inhibitor PGE ₂ for the control increase% 10 × IC ₅₀ 100 × IC ₅₀ 7, 3 ', 4'-trimethoxyflavone 23.93 314.24 3 ', 4'-dimethoxyflavones 2.84 30.94

< Example  4> 7, 3 ', 4'- On trimethoxyflavones  by HaCaT  Inside and outside the cell line PGE ₂ Level and COX , PGT  And MRP4 Confirmation of expression of

<4-1> Internal and external cells by 7, 3 ', 4'-trimethoxyflavone PGE ₂ Your level

The present inventors have found that PGE ₂ in order to determine the levels of PGE ₂ in the cell and out of the 7, 3 ', 4'-trimethoxy flavone Enzyme immunoassay was performed.

Specifically, HaCaT cells (5 × 10 ⁵ cells) were aliquoted into 6-well plates and cultured in DMEM medium at 37 ° C., 5% CO ₂ incubator. After the cultured cells were treated with 7, 3 ', 4'-trimethoxyflavone at a concentration of 50 times the IC ₅₀ value (50 x IC ₅₀ ) for 15-PGDH inhibition, cells and medium were obtained after 6 hours. It was. Increase of PGE ₂ in HaCaT cells outside the PGE ₂ The enzyme immunoassay kit (Thermo Scientific, USA) was used to measure according to the protocol accordingly.

As a result, PGE _{2 in} and out of cells when 7, 3 'and 4'-trimethoxyflavones were treated Levels increased, especially in cells with PGE ₂ Levels increased significantly (Table 3).

PGE _{2 in} and out of HaCaT cells after 7, 3 ′, 4′-trimethoxyflavone treatment level Sample name Intracellular (ng / mg protein)
(Mean ± SD) Extracellular (pg / ml)
(Mean ± SD) Control group 4.46 ± 2.34 251.7 ± 1.13 7, 3 ', 4'-trimethoxyflavone (50 × IC ₅₀ ) 8.80 ± 0.51 291.0 ± 1.96

<4-2> COX , PGT  And MRP4 of mRNA  7, 3 ', 4'-trimethoxyflavones for expression ( trimethoxyflavone , 7, 3 ', 4'- TMF ) Effect

The inventors confirmed the effect of 7, 3 ', 4'-trimethoxyflavone on the mRNA expression of COX, PGT and MRP4 affecting the PGE ₂ concentration in and out of cells by real-time PCR.

Specifically, HaCaT cells were treated with 7, 3 ′, 4′-trimethoxyflavone at a concentration of 50 × (50 × IC ₅₀ ) (20.5 uM) of the IC ₅₀ value for 15-PGDH inhibition, followed by 12 hours. Total RNA was then extracted using TRI reagents (RNAiso Plus, Takara) and the corresponding protocol. The extracted RNA 20ul was synthesized into cDNA using the Super Script First Strand kit (invitrogen) and a protocol according thereto. 4 ul of the diluted cDNA at 1: 5, 4 ul, 4 mM MgCl ₂ , 4 ul of Fast Starter Mix buffer (dNTP, SYBR Green dye and Tag polymerase), and human PGT, MRP4, and COX shown in Table 4 below. 10 pmol of primers of -1, COX-2 and beta-actin were mixed and real-time PCR was performed using Light Cyber 2.0 (Roche, Germany).

Primer Sequences for Gene Amplification Affecting PGE ₂ Concentration order SEQ ID NO: PGT
Forward primer 5'-GGATGCTG TTTGGAGGAATCCTCA-3 ' One Reverse primer 5'-GCACGATCCTGTCTTTGCTGAA-3 ' 2 MRP4
Forward primer 5'-AACCTCTAACCGACATTCCTG-3 ' 3 Reverse primer 5'-TCAACATA TTACAGCCACCATC-3 ' 4 COX-1
Forward primer 5'-CCTCATGTTTGCCTTCTTTGC-3 ' 5 Reverse primer 5'-GGC GGGTACATTTCTCCATC-3 ' 6 COX-2
Forward primer 5'-GATCTA CCCTCCTCAA-3 ' 7 Reverse primer 5'-GAACAACTGCTCATCAC-3 ' 8 Beta-actin
Forward primer 5'-GACTATGACTTAGTTGCGTTA-3 ' 9 Reverse primer 5'-GTTGAACTCTCTACATAC TTCCG-3 ' 10

As a result, the mRNA expression levels of COX-1 and PGT were almost unchanged, while the mRNA expression levels of COX-2 biosynthesizing PGE ₂ were decreased by 7, 3 'and 4'-trimethoxyflavones and released into the cell. It was confirmed that the mRNA expression level of MRP4 was increased (FIG. 3).

Thus, PGE ₂ via 15-PGDH inhibition by 7, 3 ', 4'-trimethoxyflavones Metabolic Inhibitory Effects of PGE ₂ Cells It was found to be important for increasing the level.

< Example  5> 7, 3 ', 4'- On trimethoxyflavones  Wound healing effect

We performed a wound healing assay to confirm the effect of PGE ₂ -mediated wound healing by 7, 3 ', 4'-trimethoxyflavones.

Specifically, HaCaT cells were dispensed to 5 × 10 ^{5 per} well, incubated to 80%, and replaced with serum-free DMEM medium containing 10 ug / ml of mitomycin (Sigma, USA) for 2 hours. Incubated for 2 hours. The cells were then washed with PBS solution and scraped with a 200 ul sterile pipette tip to wash off the scraped cells. Medium without added drug as a negative control to wounded cells, medium with 100 pg / ml of positive control TGF-β1 (BioVision, USA) or 15-PGDH and NAD + purified in Example 1 above. Media added together, and 20.5 uM of the experimental group 7, 3 ', 4'-trimethoxyflavone, or medium added together with 15-PGDH and NAD + for 0 hours or 48 hours, respectively, followed by reversed phase It observed with the microscope (* 100) (H-7600; Hitachi, Japan) (FIG. 4).

As a result, it was confirmed that the wound healing effect of the cells added with 7, 3 'and 4'-trimethoxyflavone was remarkable as compared with the cells added with TGF-β1, a positive control group, which was 15-PGDH, a PGE ₂ inhibitor. By confirming that the wound healing effect is inhibited when it is added, it was confirmed that the wound healing effect of 7, 3 ', 4'-trimethoxyflavone is through the inhibition of 15-PGDH.

<110> Industry-Academic Cooperation Foundation, Chosun University <120> FLAVONE COMPOUNDS WITH 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE          INHIBITORY ACTIVITY AND USES THEREOF <130> 11p-10-10 <160> 10 <170> Kopatentin 1.71 <210> 1 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> human PGT forward primer <400> 1 ggatgctgtt tggaggaatc ctca 24 <210> 2 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> human PGT reverse primer <400> 2 gcacgatcct gtctttgctg aa 22 <210> 3 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> MRP4 forward primer <400> 3 aacctctaac cgacattcct g 21 <210> 4 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> MRP4 reverse primer <400> 4 tcaacatatt acagccacca tc 22 <210> 5 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> COX-1 forward primer <400> 5 cctcatgttt gccttctttg c 21 <210> 6 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> COX-1 reverse primer <400> 6 ggcgggtaca tttctccatc 20 <210> 7 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> COX-2 forward primer <400> 7 gatctaccct cctcaa 16 <210> 8 <211> 17 <212> DNA <213> Artificial Sequence <220> <223> COX-2 reverse primer <400> 8 gaacaactgc tcatcac 17 <210> 9 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> beta-actin forward primer <400> 9 gactatgact tagttgcgtt a 21 <210> 10 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> beta-actin reverse primer <400> 10 gttgaactct ctacatactt ccg 23

Claims (10)

A pharmaceutical composition for the prevention and treatment of diseases requiring an increase in PGE ₂ selected from the group consisting of an inflammatory response disease, a tumor disease, Alzheimer's disease and atherosclerosis containing the compound of formula 1 as an active ingredient:
[Formula 1]

.
In Formula 1, R ₁ , R ₂ , R ₃ , R ₄ , R ₅ , and R ₆ are each independently hydrogen (H), hydroxy group (OH), or methoxy group (OCH ₃ ).
The pharmaceutical composition of claim 1, wherein the disease is selected from the group consisting of hair loss, scalp disease, peptic ulcer, stomatitis, oral ulcer, fracture, peripheral vascular disease, skin wound and burn.
The pharmaceutical composition of claim 2, wherein the skin wound is selected from the group consisting of cuts, wounds, cuts, abrasions and gastric ulcers.
The compound of claim 1, wherein in the compound of Formula 1, R ₁ is a methoxy group or hydrogen;
R ₂ is a methoxy group;
R ₃ is a methoxy group, hydrogen or a hydroxy group;
R ₄ is a methoxy group or hydrogen;
R ₅ is a methoxy group or hydrogen; And
Pharmaceutical composition characterized in that R ₆ is a methoxy group, hydrogen or hydroxy group.
The compound of claim 1, wherein in the compound of Formula 1, R ₁ is a methoxy group;
R ₂ is a methoxy group; And
Pharmaceutical composition, wherein R ₅ is a methoxy group.
The pharmaceutical composition of claim 1, wherein the compound of Formula 1 has an activity of inhibiting 15-hydroxyprostaglandin dehydrogenase (15-PGDH).
The pharmaceutical composition according to claim 1, wherein the compound of formula 1 has PGE ₂ increasing activity.
A cosmetic composition for hair loss, scalp improvement and skin regeneration comprising the compound of formula 1 as an active ingredient:
[Formula 1]

In Formula 1, R ₁ , R ₂ , R ₃ , R ₄ , R ₅ , and R ₆ are each independently hydrogen (H), hydroxy group (OH), or methoxy group (OCH ₃ ).
According to claim 8, In the compound of Formula 1, R ₁ Is a methoxy group or hydrogen;
R ₂ is a methoxy group;
R ₃ is a methoxy group, hydrogen or a hydroxy group;
R ₄ is a methoxy group or hydrogen;
R ₅ is a methoxy group or hydrogen; And
Cosmetic composition for hair loss, scalp improvement and skin regeneration characterized in that R ₆ is a methoxy group, hydrogen or hydroxy group.
The compound of claim 8, wherein in the compound of Formula 1, R ₁ is a methoxy group;
R ₂ is a methoxy group; And
Cosmetic composition for hair loss, scalp improvement and skin regeneration characterized in that R ₅ is a methoxy group.

Images